Abstract:

In this study, we investigated the cell viability and antioxidant effects of melatonin both with and without cisplatin (CDDP) on the cultured neuroblastoma cancer cell line. Neuroblastoma cancer cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) at 37°C with 5% CO2 to examine the cytotoxic effect of melatonin; cells were cultured both CDDP with and without melatonin and thereafter counted in a 48-well microplate. To examine the effect of melatonin and CDDP, cells were divided into ten groups (control, vehicle, melatonin-5nM and10nM, CDDP-50μM and 100μM, melatonin-5nM+CDDP- 50μM, melatonin-5nM+CDDP-100μM, melatonin-10nm+CDDP-50μM and melatonin-10nM+CDDP-100μM) and thereafter cell viability was determined in a 48-well microplate using 3-(4,5-dimetiltriazol-2-il)-2,5- difeniltetrazolium bromid (MTT) assay. In different series, cells were cultured and treated with ethanol, melatonin, CDDP, and combination of melatonin and CDDP. After harvest, TAS and TOS were measured via Elisa assay kits. Melatonin and combination of melatonin and CCDP produced no cytotoxic effect on neuroblastoma cancer cells after 24 hours, but a decrease in the cell viability after 48 hours. Furthermore, CDDP treatment significantly decreased the cell viability both after 24 and 48 hours periods compared to untreated controls. Melatonin enhanced the cytotoxic effects of CDDP after 48 hours neuroblastoma cell lines. Therefore, melatonin may be used as an adjunctive therapy agent to both improve neuroblastoma cancer chemotherapy and depression and for inhibition of CDDP side effects. J. Exp. Clin. Med., 2014; 31:37-42

Keywords: